Many patients want to heal well, return to activity, reduce downtime, and avoid a cycle of pain, inflammation, reinjury, and deconditioning
The difference between losing 30-38% of your weight from muscle versus 20-23% becomes increasingly significant as total weight loss increases
The first dual GIP/GLP-1 receptor agonist, NNC0090-2746 (also known as RG7697, RO6811135, or MAR709), is a 40-amino acid peptide acylated with a C16:0 fatty acid to lysine residue at position 40 [ Figure 2 , Table 1 ]
Patients with severe obesity, prediabetes, or those seeking rapid, sustained weight reduction typically experience superior outcomes with GLP-1 therapy
Baseline characteristics at entry